A
Adel
Develops a novel tau antibody and other pipelines for treatment of Alzheimer's disease
About Adel
ADEL is a pioneering company specializing in the development of advanced technologies for the treatment and diagnosis of Alzheimer's disease and other forms of dementia. Founded by a team of scientists from Asan Medical Center and the University of Ulsan College of Medicine in Seoul, Korea, ADEL focuses on creating innovative drug candidates aimed at improving the lives of patients globally.
Read full description
The company operates in the biotechnology and pharmaceutical markets, targeting healthcare providers, research institutions, and pharmaceutical companies. ADEL's business model revolves around research and development (R&D) of novel therapeutics and diagnostic tools, particularly focusing on tau antibodies for Alzheimer's treatment. Revenue is generated through partnerships, licensing agreements, and potential future sales of their developed drugs and diagnostic products.
ADEL's mission is to eradicate dementia and improve patient outcomes through cutting-edge science and technology. The company leverages its deep expertise in Alzheimer's research to push the boundaries of what's possible in neurodegenerative disease treatment.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Seoul, South Korea
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 57.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Adel.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2026 | $34M | $134M | InterVest · STIC Ventures · Stonebridge Ventures | ↗ |
| SERIES BOther financing | Jul 2024 | $14M | $57M | SmileGate Investment · Korea Development Bank | ↗ |
Growth signals
Latest recorded traffic for Adel is 11K monthly website visits, up 20.9% over the last three months. Adel's team grew 100% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Korea Development Bank
SmileGate Investment
Series B and later3 investors entered at this stage
Stonebridge Ventures
InterVest
STIC Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adel on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adel’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.